Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%
YSS
YSSReportable Segment — R&D
$5.29M+20.2%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Clinical operations and development14,57010,026
Research and development personnel cost and other (including stock-based compensation)9,1215,096
Research601556
Total research and development47,50034,333
General and administrative personnel costs (including stock-based compensation)7,9634,832
Professional fees3,5601,504
Facility costs, IT, office expense and other1,2191,119
Total general and administrative expenses12,7427,455

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — R&D?
Bicara Therapeutics (BCAX) reported business segments — R&D of $47.5M in Q1 2026.
How has Bicara Therapeutics's business segments — R&D changed year-over-year?
Bicara Therapeutics's business segments — R&D increased by 38.4% year-over-year, from $34.33M to $47.5M.
What is the long-term trend for Bicara Therapeutics's business segments — R&D?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — R&D has grown at a 102.1% compound annual growth rate (CAGR), from $30.62M to $125.1M.
What does business segments — R&D mean?
The aggregate expenditure dedicated to the discovery, development, and clinical testing of new pharmaceutical products. This is a primary indicator of a company's commitment to innovation and its long-term growth potential through pipeline advancement.

Ask your AI about Bicara Therapeutics's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude